Fourth-generation EGFR tyrosine kinase are in development to overcome common resistance mutations. We performed deep mutational scanning (DMS) of the EGFR kinase domain in the context of L858R by intr
Additional file 6. Table S6A, B. Over-represented hallmark gene sets among genes up- and down-regulated with increasing resistance in MaMel cell lines.
The clinical efficacy of EGFR kinase inhibitors gefitinib and erlotinib is limited by the development of drug resistance. The most common mechanism of drug resistance is the secondary EGFR T790M mut
